Clinical Trial Update: Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib as first- or second-line treatment for EGFR-mutated non-small cell lung cancer using circulating tumor DNA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Chonnam National University Hospital | Conditions: Lung Neoplasms, EGFR Gene Mutations | Phase 2 | Status: COMPLETED